dc.creator | Pagkopoulou E., Simopoulou T., Maragkouli E., Perifanou-Sotiri S., Kotsakis A., Bogdanos D.P. | en |
dc.date.accessioned | 2023-01-31T09:41:19Z | |
dc.date.available | 2023-01-31T09:41:19Z | |
dc.date.issued | 2020 | |
dc.identifier | 10.31138/mjr.31.3.355 | |
dc.identifier.issn | 24593516 | |
dc.identifier.uri | http://hdl.handle.net/11615/77426 | |
dc.description.abstract | Immune checkpoint inhibitors (ICIs) are a new class of drug that have demonstrated efficacy across many cancer types. Because of their nature and mode of action, ICIs unleash immune activation raising concerns as to whether they can be used in patients with concomitant autoimmune or autoinflammatory diseases. Their usage can lead to the development of autoimmune phenomena known as immune related adverse events (irAEs), virtually affecting every organ. As the use of ICIs is drastically increasing, evidence of irAEs has been accumulating. Herein, we report a case of inflammatory myositis and arthritis 6 months after pembrolizumab therapy, an anti-programmed death-1 (PD1) ICI in a patient with lung cancer, aiming at raising awareness of the diagnostic and clinical challenges clinicians may face when checkpoint inhibitors-related rheumatologic irAEs are developed. © 2020 | en |
dc.language.iso | en | en |
dc.source | Mediterranean Journal of Rheumatology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106545668&doi=10.31138%2fmjr.31.3.355&partnerID=40&md5=bb36a38d4453c3068bfba0962127621c | |
dc.subject | antinuclear antibody | en |
dc.subject | C reactive protein | en |
dc.subject | creatine kinase | en |
dc.subject | methotrexate | en |
dc.subject | pembrolizumab | en |
dc.subject | prednisone | en |
dc.subject | programmed death 1 ligand 1 | en |
dc.subject | rivaroxaban | en |
dc.subject | adult | en |
dc.subject | antibody titer | en |
dc.subject | Article | en |
dc.subject | autoimmune disease | en |
dc.subject | cancer patient | en |
dc.subject | case report | en |
dc.subject | Caucasian | en |
dc.subject | clinical article | en |
dc.subject | creatine kinase blood level | en |
dc.subject | deep vein thrombosis | en |
dc.subject | electromyography | en |
dc.subject | erythrocyte sedimentation rate | en |
dc.subject | hospital admission | en |
dc.subject | human | en |
dc.subject | human tissue | en |
dc.subject | immunohistochemistry | en |
dc.subject | knee arthritis | en |
dc.subject | lung adenocarcinoma | en |
dc.subject | male | en |
dc.subject | middle aged | en |
dc.subject | muscle weakness | en |
dc.subject | myositis | en |
dc.subject | patient referral | en |
dc.subject | protein blood level | en |
dc.subject | protein expression | en |
dc.subject | treatment duration | en |
dc.subject | Greek Rheumatology Society and Professional Association of Rheumatologists | en |
dc.title | Arthritis and Myositis in a Patient Treated with Programmed Cell Death-1 (PD-1) Inhibitor Pembrolizumab for Lung Cancer | en |
dc.type | journalArticle | en |